<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749667</url>
  </required_header>
  <id_info>
    <org_study_id>159326</org_study_id>
    <nct_id>NCT04749667</nct_id>
  </id_info>
  <brief_title>Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis</brief_title>
  <acronym>SMART-MS</acronym>
  <official_title>Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate neuroregenerative efficacy (proof of&#xD;
      concept) of intrathecal treatment with autologous MSCs as measured by neurophysiological&#xD;
      parameters in patients with progressive MS.&#xD;
&#xD;
      Secondary objectives are to assess neuroregenerative efficacy as measured by other&#xD;
      neurophysiological parameters as well as clinical, opthalmological and MRI modalities, and to&#xD;
      assess safety of the treatment procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, interventional, randomized, placebo-controlled, cross-over study. Patients are&#xD;
      randomized to either treatment arm A or B.&#xD;
&#xD;
      Patients in both treatment arms receive intrathecal autologous MSCs, arm A at baseline and&#xD;
      arm B at six months.&#xD;
&#xD;
      All patients undergo bone marrow (BM) aspiration prior to baseline. Patients in treatment arm&#xD;
      A receive intrathecal autologous MSCs whereas patients in treatment arm B receive placebo.&#xD;
      The treatment is blinded for the patients. The BM aspirate from patients in treatment arm B&#xD;
      is processed, cryopreserved and stored in a biobank.&#xD;
&#xD;
      At six months, all patients undergo a second BM aspiration. Patients in treatment arm A now&#xD;
      receive placebo. The BM aspirate from patients in treatment arm A is processed, cryopreserved&#xD;
      and stored in a biobank. Patients in treatment arm B receive intrathecal autologous MSCs. The&#xD;
      treatment is blinded for the patients.&#xD;
&#xD;
      Primary outcome is assessed at six months and secondary outcomes are assessed at six, twelve&#xD;
      and eighteen months post baseline. Investigator assessing outcomes are blinded to patient&#xD;
      treatment allocation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">January 4, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, placebo-controlled, cross-over study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurophysiological parameters - Combined evoked potentials</measure>
    <time_frame>6 months</time_frame>
    <description>Somatosensoric evoked potentials (SEP) + visual evoked potentials (VEP) + motor evoked potentials (MEP), latency (ms) and amplitude (mV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological parameters - Somatosensoric evoked potantials</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>SEP, latency (ms) and amplitude (mV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological parameters - Motor evoked potentials</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>MEP, latency (ms) and amplitude (mV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological parameters - Visual evoked potentials</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>VEP, latency (ms) and amplitude (mV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI-Lesion volumes</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>T1- and T2-weighted hyperintense lesion volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR- Brain volumes</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Brain volumes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded disability status scale</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>EDSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (PROs)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), European Quality of Life 5 dimensions (EQ-5D-5L), Multiple Sclerosis Impact Scale (MSIS) and Fatigue severity scale (FSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine-Hole-Peg Test (9-HPT)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Nine-Hole-Peg Test (9-HPT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25 Foot Walk (T25FW)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Timed 25 Foot Walk (T25FW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual function</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Visual acuity, visual field, color vision and contrast sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography (OCT)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Retinal thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and nature of adverse- and serious adverse events</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arm A - Crossover with MSCs at baseline and placebo at 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives mesenchymal stem cells at baseline and placebo at 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Crossover with placebo at baseline and MSCs at 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives placebo at baseline and mesenchymal stem cells at 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MSCs</intervention_name>
    <description>Autologous bone-marrow derived mesenchymal stem cells</description>
    <arm_group_label>Arm A - Crossover with MSCs at baseline and placebo at 6 months</arm_group_label>
    <arm_group_label>Arm B - Crossover with placebo at baseline and MSCs at 6 months</arm_group_label>
    <other_name>Mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Isotonic saline</description>
    <arm_group_label>Arm A - Crossover with MSCs at baseline and placebo at 6 months</arm_group_label>
    <arm_group_label>Arm B - Crossover with placebo at baseline and MSCs at 6 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 to ≤55, both genders&#xD;
&#xD;
          2. Diagnosis of secondary progressive or primary progressive MS using revised McDonald&#xD;
             criteria of clinically definite MS&#xD;
&#xD;
          3. An EDSS score of 4 to 7&#xD;
&#xD;
          4. Disease duration 2 - 15 years&#xD;
&#xD;
          5. Signed, written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any illness or prior/ongoing treatment that in the opinion of the investigators would&#xD;
             jeopardize the ability of the patient to tolerate autologous stem cell treatment&#xD;
&#xD;
          2. Any ongoing infection, including Tbc, CMV, EBV, HSV, VZV, hepatitis virus,&#xD;
             toxoplasmosis, HIV or syphilis infections, as well as heaptitis B surface antigen&#xD;
             positivity and/or hepatitis C PCR positivity&#xD;
&#xD;
          3. Current immunomodulatory/immunosuppressive treatment&#xD;
&#xD;
          4. Immunomodulatory/immunosuppressive treatment within 6 months prior to inclusion. This&#xD;
             includes, but is not restricted to treatment with natalizumab, fingolimod,&#xD;
             dimetylfumurat, glatiramer acetate, interferon beta medications, teriflunomide, and&#xD;
             siponimod.&#xD;
&#xD;
          5. Treatment with kladribin, ocrelizumab, rituximab, and alemtuzumab within 12 months&#xD;
             prior to inclusion&#xD;
&#xD;
          6. Treatment with hematopoietic stem cell therapy within 12 months prior to inclusion&#xD;
&#xD;
          7. Treatment with glucocorticoids or ACTH within three months prior to start of inclusion&#xD;
&#xD;
          8. Having experienced an MS relapse within 2 years prior to study inclusion&#xD;
&#xD;
          9. Current treatment with fampridin&#xD;
&#xD;
         10. History of malignancy other than basal cell carcinoma of the skin or carcinoma in situ&#xD;
             that has been in remission for more than one year&#xD;
&#xD;
         11. Severely limited life expectancy by another co-morbid illness&#xD;
&#xD;
         12. History of previous diagnosis of myelodysplasia or previous hematologic disease&#xD;
             (including lymphoproliferative disease, bone marrow insufficiency or previous lymphoid&#xD;
             irradiation) or current clinically relevant abnormalities of white blood cell counts&#xD;
&#xD;
         13. Immunocompromised patients&#xD;
&#xD;
         14. Estimated glomerular filtration rate &lt;60 ml/min/1.73 m2 or known renal failure&#xD;
&#xD;
         15. Bleeding or clotting diathesis or the use of antithrombotic or anticoagulative&#xD;
             treatment&#xD;
&#xD;
         16. Platelet (thrombocyte) count &lt;100 x 10*9/L&#xD;
&#xD;
         17. Participation in another experimental clinical study within the preceding 12 months&#xD;
&#xD;
         18. Contraindications to MRI&#xD;
&#xD;
         19. Prior or current major depression&#xD;
&#xD;
         20. Prior or current psychiatric illness, mental deficiency or cognitive dysfunction&#xD;
             influencing the patient ability to make an informed consent or comply with the&#xD;
             treatment and follow-up phases of this protocol.&#xD;
&#xD;
         21. Pregnancy or risk of pregnancy (this includes patients that are unwilling to practice&#xD;
             active contraception during the duration of the study), breastfeeding or lactation&#xD;
&#xD;
         22. History of autologous/allogenic bone marrow transplantation or peripheral blood cell&#xD;
             transplant&#xD;
&#xD;
         23. Known hypersensitivity against paracetamol, codein or xylocain&#xD;
&#xD;
         24. Diagnosis or strong suspicion of polyneuropathy&#xD;
&#xD;
         25. Prior or current alcohol or drug dependencies&#xD;
&#xD;
         26. Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Bø, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Bø, Prof</last_name>
    <phone>559750000</phone>
    <phone_ext>0047</phone_ext>
    <email>lars.bo@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Elnan Kvistad, PhD</last_name>
    <phone>559750000</phone>
    <phone_ext>0047</phone_ext>
    <email>echr@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <state>Troms Og Finnmark</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margitta Kampman, PhD</last_name>
      <phone>77626000</phone>
      <phone_ext>0047</phone_ext>
      <email>margitta.kampman@unn.no</email>
    </contact>
    <investigator>
      <last_name>Margitta Kampman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.Olav university hospital</name>
      <address>
        <city>Trondheim</city>
        <state>Trøndelag</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristin Wesnes, PhD</last_name>
      <phone>72573000</phone>
      <phone_ext>0047</phone_ext>
      <email>Kristin.wesnes@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Kristin Wesens, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Vestland</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Elnan Kvistad, PhD</last_name>
      <phone>559750000</phone>
      <email>echr@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Christopher Elnan Kvistad, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus university hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Viken</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trygve Hospital, Prof</last_name>
      <phone>67960000</phone>
      <email>trygve.holmoy@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Trygve Holmøy, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

